Evansville,, Indiana-headquartered Berry Global Group Inc., will begin product production at its new manufacturing facility and healthcare center of excellence in Bangalore, in April 2023.
According to the company, leveraging the company’s research and development solutions, this new Greenfield expansion project will improve regional and global access to advanced healthcare solutions and provide customers with necessary volume to support the forecasted growth for Asia’s domestic healthcare market.
The new Bangalore plant will provide access to products for the Inhalation, Nasal, Ophthalmic, Dispensing, and Self-injection industries. The new Berry Global Healthcare R&D Center of Excellence will support the development of innovative solutions for existing and new applications. The Bangalore site’s ability to cater pharmaceutical packaging to U.S. regulatory requirements will enable the local manufacture of healthcare products, at a global scale.
The R&D center will launch up to seven new products and projects in 2023 ranging from DPI Inhalers to plastics caps and closures. Included among these products will be Berry’s Pneumohaler, a lightweight, breath-actuated, multidose inhaler dose counter for the control and treatment of Asthma and Chronic Obstructive Pulmonary Disease.
